Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2004-01-15
2008-03-25
Sullivan, Daniel M (Department: 1636)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C514S328000
Reexamination Certificate
active
07348000
ABSTRACT:
A method for treating a glycolipid storage-related disorder, comprising administering a therapeutically effective amount of an inhibitor of glycolipid synthesis in combination with an agent capable of increasing the rate of glycolipid degradation or in combination with bone marrow transplantation. Inhibitors of glycolipid synthesis include N-butyldeoxynojirimycin (NB-DNJ), N-butyldeoxygalactonojirimycin (NB-DGJ) or N-nonyldeoxynojirimycin (NN-DNJ). Glycolipid storage-related disorders include Gaucher disease, Sandhoff's disease, Fabry's disease, Tay-Sach's disease, Niemann-Pick C storage disease, GM1 gangliosidosis, genetic disorders in which neuronal glycolipid accumulation contributes to disease pathology.
REFERENCES:
patent: 4182767 (1980-01-01), Murai et al.
patent: 4266025 (1981-05-01), Kinast et al.
patent: 4405714 (1983-09-01), Kinast et al.
patent: 5151519 (1992-09-01), Behling et al.
patent: 5580884 (1996-12-01), Platt et al.
patent: 5786368 (1998-07-01), Platt et al.
patent: 6291657 (2001-09-01), Platt et al.
patent: WO 98/02161 (1998-01-01), None
Ross G, Erickson R, Knorr D, Motulsky AG, Parkman R, Samulski J, Straus SE, Smith BR. Gene therapy in the United States: a five-year status report. Hum Gene Ther. Sep. 10, 1996;7(14):1781-90.
Marshall E. Gene therapy's growing pains. Science. Aug. 25, 1995;269(5227):1050, 1052-5.
Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature. Sep. 18, 1997;389(6648):239-42.
Orkin SH and Motulski AG. Report and REcommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995.
Rubanyi GM. The future of human gene therapy. Mol Aspects Med. Jun. 2001;22(3):113-42.
Choo-Smith et al., Biol Chem, 272:22987-90 (1997).
Cox et al., The Lancet, 355:1481-1485 (2000).
Jeyakumar et al., Proc. Natl. Acad. Sci. USA, 96:6388-6393 (1999).
Meuilet et al., Experimental Cell Research, 256:74-85 (2000).
Overkleeft et al., J. Biol. Chem., 273:26522-26527 (1998).
Platt et al., Biochemical Pharmacology, 56:421-30 (1998).
Platt et al., J. Biol. Chem., 269:8362-6 (1994).
Platt et al., Science, 276:428-31 (1997).
Platt et al., J. Biol. Chem., 269:27108-27114 (1994).
Radin et al.,Glycoconj, J., 13:153-7 (1996).
Rosner et al., Ann N Y Acad Sci., 845:200-14 (1998).
Zervas et al., Current Biology, 11:1283-1287 (2001).
Beutler et al., Blood, 78:1183-1189 (1991).
Fredman et al., Glycoconjugate Journal, 13:391-399 (1996).
Glinsky et al., Cancer Research, 56:5319-5324 (1996).
Grabowski et al., Ann Intern Med., 122:33-39 (1995).
Yanagisawa et al., Nature Medicine, 1:1062-1067 (1995).
N. Asano et al., Tetrahedron:Asymmetry, 11:1645-1680 (2000).
D.A. Priestman et al., Glycobiology, 10:iv-vi (2000).
Gopalan et al., Kinetic analysis of the interaction of alkyl glycosides with two human β-glucosidases, Biochem J.,1989, 262:541-548.
Gatt et al., Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase, Enzyme, 1985, 33(2):109-19, (Abstract Only).
Grabowski et al., Human Acid β-Glucosidase, The Journal of Biological Chemistry, 1986, 261:8263-8269.
Grace et al., Analyses of Catalytic Activity and Inhibitor Binding of Human Acid β-Glucosidase by Site-directed Mutagenesis, The Journal of Biological Chemistry, 1990, 265:6827-6835.
Warren et al., The effects ofN-hexyl-O-glucosyl sphingosine on normal cultured human fibroblasts: a chemical model for Gaucher's disease, Journal of Lipid Research, 1976, 17:132-138.
Shafit-Zagardo et al., Human beta-glucosidase: inhibition by sulphates and purification by affinity chromatography on Dextran-sulphate-Sepharose, Biochim Biophys Acta, May 14, 1981, 659(1):7-14 (Abstract Only).
Blonder et al., Effects of detergents and choline-containing phospholids on human spleen glucocerebrosidase, Biochim Biophys Acta, Apr. 22, 1976, 431(1):45-53 (Abstract Only).
Saul et al., Castanospermine, a tetrahydroxylated alkaloid that inhibits beta-glucosidase and beta-glucocerebrosidase, Arch Biochem Biophys, Mar. 22, 1983, 221(2):593-7 (Abstract Only).
Sano et al., The inhibition of glucosylceramide β-glucosidase and other acid hydrolases by nucleic acids, Biochem J., 1988, 254:297-300.
Platt et al., Inhibitors of Glycosphingolipid Biosynthesis, Trends in Glycoscience and Glycotechnology, 1995, 7:495-511.
Butters Terence D.
Dwek Raymond A.
Jeyakumar Mylvaganam
Platt Frances Mary
Priestman David
Actelion Pharmaceuticals Ltd
Klauber & Jackson
Sullivan Daniel M
LandOfFree
Therapeutic compositions and methods of treating glycolipid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions and methods of treating glycolipid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions and methods of treating glycolipid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963609